2007-10-04 GSK applies for licence to market OTC weight loss product In Europe

So far, alli is performing well in the US and, if our application is successful, we will commit to rolling out a similar responsible marketing campaign with the same level of support for consumers in Europeas we have done in the US. We want to see people achieving gradual, sustained weight loss by using alli in tandem with a healthy eating, low-fat diet and increased exercise. Weve said all along that this is no magic pill. If people are looking for a quick fix, this is not it but it is a powerful motivator, helping people lose up to 50 pct. more weight than with diet alone*.

www.webwire.com

For business and financial media, , , , GlaxoSmithKline (GSK) today announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agen. - For business and financial media GlaxoSmithKline (GSK) today announced its marketing application for non-prescription orlistat 60mg for weight loss has been